Table 3 SARS-CoV-2-specific antibody titers in relation to detectable SARS-CoV-2 RNA and infectious SARS-CoV-2 in nasopharynx in all COVID-19 patients (n = 36).
Total SARS- CoV-2 IgG titer | Number of patients | PCR Positive | PCR negative | Culture positive | Culture negative | ||||
no. | % | no. | % | no. | % | no. | % | ||
< 20 | 2 | 2 | 100 | 0 | 0 | 2 | 100 | 0 | 0 |
20 to 40 | 5 | 3 | 60 | 2 | 40 | 2 | 40 | 3 | 60 |
160 to 320 | 4 | 3 | 75 | 1 | 25 | 0 | 0 | 4 | 100 |
640 to 2560 | 25 | 6 | 24 | 19 | 76 | 0 | 0 | 25 | 100 |
Neutralizing antibody titer | Number of patients | PCR Positive | PCR negative | Culture positive | Culture negative | ||||
no. | % | n | % | no. | % | no. | % | ||
< 10 | 3 | 3 | 100 | 0 | 0 | 3 | 100 | 0 | 0 |
10 to 15 | 5 | 4 | 67 | 2 | 33 | 1a | 17 | 5 | 83 |
30 to 120 | 18 | 7 | 41 | 10 | 59 | 0 | 0 | 17 | 100 |
160 to 580 | 10 | 0 | 0 | 10 | 100 | 0 | 0 | 10 | 100 |